Cancer Vaccine Technology
Creative Biolabs pioneers innovative cancer vaccine technologies, offering cutting-edge platforms to accelerate immune-oncology research. Our solutions span from antigen presentation enhancement to immune response modulation, leveraging advanced methodologies like tumor-apc fusion technology and cytokine development to boost vaccine immunogenicity. We specialize in immune monitoring assays, such as ELISpot and tetramer analysis, to quantify T-cell responses and validate vaccine efficacy. Our anti-treg immune-modulating technology targets immunosuppressive tumor microenvironments, while biomarker discovery via high-throughput sequencing identifies predictive markers for personalized vaccine design. Additionally, technologies like microfluidic cell squeezing and antibody-antigen fusion enable precise antigen delivery, while MHC class II-associated II protein suppression and TLR9 agonist development enhance antigen presentation and innate immune activation. With the integration of vaccine combination immunotherapy, we optimize multi-modal strategies to overcome tumor resistance, ensuring comprehensive support for preclinical and clinical development.
Tumor-APC Fusion Technology: Develops hybrid cell vaccines by fusing tumor cells with antigen-presenting cells (APCs) to enhance antigen presentation and induce robust anti-tumor immunity.
Immune Monitoring Assay of Cancer Vaccine: Offers validated assays (ELISpot, flow cytometry) to quantify antigen-specific T-cell responses and evaluate vaccine-induced immunity.
Cytokine Development to Enhance Antigen Presentation: Utilizes cytokines (e.g., IL-2, GM-CSF) to create pro-inflammatory tumor microenvironments, improving dendritic cell maturation and immune activation.
Anti-Treg Immune-modulating Anti-Cancer Technology: Targets regulatory T cells (Tregs) and immunosuppressive pathways (e.g., IDO, PD-1/PD-L1) to restore anti-tumor immune responses.
Vaccine Combination Immunotherapy: Integrates vaccines with chemotherapy, radiation, or checkpoint inhibitors to enhance therapeutic efficacy and overcome immune resistance.
Biomarker Discovery Technology for Cancer Vaccine: Employs next-generation sequencing and omics to identify predictive biomarkers for vaccine efficacy and patient stratification.
Microfluidic Cell Squeezing Technology for B Cell based Vaccine: Uses mechanical deformation to deliver antigens into B cells, enhancing their role as antigen-presenting cells for vaccine development.
Antibody-Antigen Fusion Technology for Cancer Vaccine: Creates targeted conjugates of antibodies with antigens, toxins, or cytokines to improve vaccine specificity and immune activation.
MHC Class II associated li Protein Suppression Technology: Inhibits the invariant chain (II) to enhance MHC Class II presentation of endogenous antigens, boosting CD4+ T cell activation.
Toll-Like Receptor 9 Agonist Development Technology: Develops CpG oligonucleotides to activate TLR9, inducing Th1-type immune responses and enhancing vaccine adjuvancy.
Unlock the Future of Cancer Immunotherapy
Whether you’re optimizing antigen presentation, validating immune responses, or developing novel combination therapies, Creative Biolabs provides tailored solutions backed by decades of expertise. Our multidisciplinary team offers end-to-end support, from technology selection to GMP manufacturing, ensuring your project’s success. Don’t miss the opportunity to leverage our state-of-the-art platforms and collaborative approach. Contact us via email or visit our website to discuss how our cancer vaccine technologies can drive your research toward breakthrough innovations in immunotherapy.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
